PCSK9 and chronic obstructive pulmonary disease: Whilst further genetic and clinical evidence is needed to confirm (or refute) these findings, they raise the possibility that, in individuals with pre-existing COPD, a careful risk-benefit evaluation of LDL-C lowering through inhibition of PCSK9 may be required.